Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Clinical Manifestations of the anti-IgLON5 Disease
Neurol 88:1736-1743,1688, Gaig, C.,et al, 2017
Neuroimaging Changes in Menkes Disease, Part 1
AJNR 38:1850-1857, Manara, R.,et al, 2017
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
Tau Forms in CSF as a Reliable Biomarker for Progressive Supranuclear Palsy
Neurol 71:1796-1803, Borroni,B.,et al, 2008
Clinical,Neuroimaging,and Genetic Markers in Cerebral Amyloid Angiopatny-Related Inflammation:A Systematic Review and Meta-Analusis
Stroke 54:178-188, Theodorou,A.,et al, 2023
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Blood-based NfL - A biomarker for differential diagnosis of parkinsonian disorder
Neurol 88:930-937,922, Hansson, O.,et al, 2017
Noncontrast Computed Tomography Markers of Intracerebral Hemorrhage Expansion
Stroke 48:1120-1125, Boulouis, G.,et al, 2017
Diagnosis and Management of Dementia with Lewy Bodies
Neurol 89:88-100, McKeith, I.G.,et al, 2017
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
The Autosomal Recessive Cerebellar Ataxias
NEJM 366:636-646, Anheim,M.,et al, 2012
Infarct Volume is a Pivotal Biomarker After Inter-Arterial Stroke Therapy
Stroke 43:1323-1330, Yoo,A.J.,et al, 2012
Paraneoplastic and Autoimmune Encephalitis
UpToDate, June, Dalmau, J.,et al, 2011
Primary Central Nervous System Lymphoma
Arch Neurol 67:291-297, Gerstner,E.R. &Batchelor,T.T., 2010
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
NMO-IgG Predicts the Outcome of Recurrent Optic Neuritis
Neurol 70:2197-2200, Matiello,M.,et al, 2008
Serum Uric Acid and Clinical Progression in Parkinson Disease: Potential Biomarker for Nigrostriatal Failure
Arch Neurol 65:698-699, Schiess,M. &Oh,I., 2008
Outcome in Adult Low-Grade Glioma: The Impact of Prognostic Factors and Treatment
Neurol 69:1366-1373, Schiff,D.,et al, 2007
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome
Neurol 96:848-863, Katz, D.I.,et al, 2021
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
A 60-year-old woman with ataxia
Neurol 90:e1627-e1630, Dandapat, S.,et al, 2018
Neurofilament as a Blood Marker for Diagnosis and Monitoring of Primary Progressive Aphasias
Neurol 88:961-969, Steinacker, P.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
A Clinical Approach to the Diagnosis of Traumatic Encephalopathy Syndrome
JAMA Neurol 73:743-749, Reams, N.,et al, 2016
Aphasic Variant of Alzheimer Disease
Neurol 87:1337-1343, Rogalski, E.,et al, 2016
Parkinson Disease Subtypes
JAMA 71:499-504, Thenganatt, M. & Jankovic, J., 2014
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Fully-Automated Quantification of Regional Brain Volumes for Improved Detection of Focal Atrophy in Alzheimers Disease
AJNR 30:578-580, Brewer, J.B.,et al, 2009
Biochemical Markers in Persons With Preclinical Familial Alzheimer Disease
Neurol 71:85-92,78, Ringman,J.M.,et al., 2008